Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Corcept Therapeutics Q4 Loss Widens

Corcept Therapeutics Inc. (CORT: Quote) reported a fourth-quarter net loss of $9.9 million, or $0.12 per share, compared to a net loss of $7.1 million, or $0.10 per share, for the fourth quarter of 2010.

Research and development expenses increased to $6.6 million, from $4.7 million in the year ago quarter.

During the comparable periods, research and development expenses increased primarily due to higher costs associated with the submission and prosecution of our NDA for Korlym, purchase of Korlym's active pharmaceutical ingredient, manufacture of Korlym tablets and manufacturing development activities.

Click here to receive FREE breaking news email alerts for Corcept Therapeutics Inc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
After initially showing a lack of direction, stocks have moved sharply lower over the course of the trading day on Thursday. The losses on the day are extending a recent downward trend by the markets, with the major averages falling to their lowest levels in over a month. After reporting a sharp jump in new orders for U.S. manufactured goods in the previous month, the Commerce Department released a report on Thursday showing that factory orders pulled back by a little more than expected in the month of August. First-time claims for U.S. unemployment benefits unexpectedly decreased in the week ended September 27th, according to a report released by the Labor Department on Thursday. The report said initial jobless claims fell to 287,000, a decrease of 8,000 from the previous week's revised level of 295,000.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.